NCT04560673: Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have had neuropathic symptoms for a minimum of 3 months & no plans to change pain medication regimen during the course of the study
Exclusions: Patients with unstable, symptomatic, uncontrolled brain metastases and/or leptomeningeal disease- see trial for details

Comments are closed.

Up ↑